REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Revenues and Disaggregates Net Product Revenues by Product (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue from External Customer [Line Items]
Revenue	$ 2,419,226	$ 2,096,039	$ 1,846,275
Product
Revenue from External Customer [Line Items]
Revenue	2,372,538	2,042,025	1,783,498
Total enzyme product revenues
Revenue from External Customer [Line Items]
Revenue	1,718,401	1,645,320	1,491,867
VIMIZIM
Revenue from External Customer [Line Items]
Revenue	701,053	663,739	623,145
NAGLAZYME
Revenue from External Customer [Line Items]
Revenue	420,292	443,794	380,449
PALYNZIQ
Revenue from External Customer [Line Items]
Revenue	303,919	255,032	237,474
BRINEURA
Revenue from External Customer [Line Items]
Revenue	161,889	154,333	128,034
ALDURAZYME
Revenue from External Customer [Line Items]
Revenue	131,248	128,422	122,765
ALDURAZYME | Marketed by Sanofi
Revenue from External Customer [Line Items]
Revenue	131,248	128,422	122,765
VOXZOGO
Revenue from External Customer [Line Items]
Revenue	469,881	169,128	5,855
KUVAN
Revenue from External Customer [Line Items]
Revenue	180,767	227,577	285,776
ROCTAVIAN
Revenue from External Customer [Line Items]
Revenue	3,489	0	0
Royalty and other revenues
Revenue from External Customer [Line Items]
Revenue	$ 46,688	$ 54,014	$ 62,777